Patients hospitalized with alcohol-related liver disease and prior bariatric surgery are more prone to develop acute-on-chronic liver failure.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
Dec 2023
Historique:
revised: 17 08 2023
received: 19 06 2023
accepted: 29 08 2023
medline: 29 11 2023
pubmed: 18 9 2023
entrez: 18 9 2023
Statut: ppublish

Résumé

Patients with a history of bariatric surgery (BS) are susceptible to developing alcohol use disorder. We and others have previously shown that these patients can develop severe alcohol-related liver disease (ARLD). Our aim was to describe the demographics, co-morbidities and mortality of a hospitalized population diagnosed with alcohol-related liver disease, in relation to BS. We included 299 patients hospitalized with ARLD at the Ghent University Hospital between 1 January 2018 and 31 December 2022. Clinical, biochemical and outcome data were retrospectively retrieved from the most recent hospitalization. Statistical analysis was performed using the t test, Mann-Whitney U and χ Thirteen per cent (39/299) of patients admitted with ARLD had a history of bariatric surgery, of whom 25 (64.1%) had undergone Roux-en-Y gastric bypass. Patients with a history of BS were predominantly female (76.9%), in contrast to the non-BS population (29.2%) (p < .0001), and despite being significantly younger (p < .0001) and had a similar survival (61.5% vs. 58.1%). Bariatric surgery and older age at diagnosis were both significantly associated with poorer transplant-free survival. The cause of death was acute-on-chronic liver failure in 73.3% of BS patients, compared to only 19.2% of those without a history of BS (p < .0001). The weekly amount of alcohol consumed (p = .012) and duration of use (p < .0001) were significantly lower/shorter in the BS population. BS patients hospitalized with ARLD are predominantly younger women with a lower cumulative alcohol consumption compared to those without prior BS. BS impacted transplant-free survival, with ACLF as the predominant cause of death in these patients.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Patients with a history of bariatric surgery (BS) are susceptible to developing alcohol use disorder. We and others have previously shown that these patients can develop severe alcohol-related liver disease (ARLD). Our aim was to describe the demographics, co-morbidities and mortality of a hospitalized population diagnosed with alcohol-related liver disease, in relation to BS.
METHODS METHODS
We included 299 patients hospitalized with ARLD at the Ghent University Hospital between 1 January 2018 and 31 December 2022. Clinical, biochemical and outcome data were retrospectively retrieved from the most recent hospitalization. Statistical analysis was performed using the t test, Mann-Whitney U and χ
RESULTS RESULTS
Thirteen per cent (39/299) of patients admitted with ARLD had a history of bariatric surgery, of whom 25 (64.1%) had undergone Roux-en-Y gastric bypass. Patients with a history of BS were predominantly female (76.9%), in contrast to the non-BS population (29.2%) (p < .0001), and despite being significantly younger (p < .0001) and had a similar survival (61.5% vs. 58.1%). Bariatric surgery and older age at diagnosis were both significantly associated with poorer transplant-free survival. The cause of death was acute-on-chronic liver failure in 73.3% of BS patients, compared to only 19.2% of those without a history of BS (p < .0001). The weekly amount of alcohol consumed (p = .012) and duration of use (p < .0001) were significantly lower/shorter in the BS population.
CONCLUSIONS CONCLUSIONS
BS patients hospitalized with ARLD are predominantly younger women with a lower cumulative alcohol consumption compared to those without prior BS. BS impacted transplant-free survival, with ACLF as the predominant cause of death in these patients.

Identifiants

pubmed: 37718533
doi: 10.1111/liv.15726
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2743-2751

Subventions

Organisme : Research Foundation - Flanders (FWO)
ID : 1801721N
Organisme : Research Foundation - Flanders (FWO)
ID : 1805718N
Organisme : Research Foundation - Flanders (FWO)
ID : 12R0321N

Informations de copyright

© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61-116. doi:10.1016/S0140-6736(21)01701-3/ATTACHMENT/82513520-DAB3-430E-A196-83F57E6FC6C3/MMC1.PDF
Bertola A. Mouse model of alcoholic steatohepatitis. Methods Mol Biol. 2020;2164:145-157. doi:10.1007/978-1-0716-0704-6_15
Thursz M, Gual A, Lackner C, et al. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181. doi:10.1016/J.JHEP.2018.03.018
Blackburn AN, Hajnal A, Leggio L. The gut in the brain: the effects of bariatric surgery on alcohol consumption. Addict Biol. 2017;22(6):1540-1553. doi:10.1111/ADB.12436
Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59(1):160-168. doi:10.1016/j.jhep.2013.03.007
Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61(2):141-152. doi:10.1111/J.1365-2559.2011.04145.X
Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015;39(5):763-775. doi:10.1111/acer.12704
Tobias DK, Hu FB. The association between BMI and mortality: implications for obesity prevention. Lancet Diabetes Endocrinol. 2018;6(12):916-917. doi:10.1016/S2213-8587(18)30309-7
Bhaskaran K, dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944-953. doi:10.1016/S2213-8587(18)30288-2
Hua R, Wang GZ, Shen QW, et al. Sleeve gastrectomy ameliorated high-fat diet (HFD)-induced non-alcoholic fatty liver disease and upregulated the nicotinamide adenine dinucleotide +/ Sirtuin-1 pathway in mice. Asian J Surg. 2021;44(1):213-220. doi:10.1016/J.ASJSUR.2020.05.030
Andolfi C, Fisichella PM. Epidemiology of obesity and associated comorbidities. J Laparoendosc Adv Surg Tech A. 2018;28(8):919-924. doi:10.1089/LAP.2018.0380
Chen G, Zhang GX, Peng BQ, Cheng Z, Du X. Roux-En-Y gastric bypass versus sleeve gastrectomy plus procedures for treatment of morbid obesity: systematic review and meta-analysis. Obes Surg. 2021;31(7):3303-3311. doi:10.1007/s11695-021-05456-0
Morton JM. The ASMBS textbook of bariatric surgery; 2020. doi:10.1007/978-3-030-27021-6
Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev. 2009;15(2):CD003641. doi:10.1002/14651858.CD003641.PUB3
Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg. 2017;27(9):2279-2289. doi:10.1007/S11695-017-2666-X
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737. doi:10.1001/JAMA.292.14.1724
Jammu GS, Sharma R. A 7-year clinical audit of 1107 cases comparing sleeve gastrectomy, roux-En-Y gastric bypass, and mini-gastric bypass, to determine an effective and safe bariatric and metabolic procedure. Obes Surg. 2016;26(5):926-932. doi:10.1007/S11695-015-1869-2
Ferstl P, Trebicka J. Acute decompensation and acute-on-chronic liver failure. Clin Liver Dis. 2021;25(2):419-430. doi:10.1016/J.CLD.2021.01.009
Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL). Hepatol Int. 2009;3(1):269-282. doi:10.1007/S12072-008-9106-X
Singh H, Pai CG. Defining acute-on-chronic liver failure: east, west or middle ground? World J Hepatol. 2015;7(25):2571-2577. doi:10.4254/WJH.V7.I25.2571
Li F, Thuluvath PJ. EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF. J Hepatol. 2021;75(5):1096-1103. doi:10.1016/J.JHEP.2021.05.033
Verma N, Mehtani R, Duseja A. Universal definition and prognostication in acute-on-chronic liver failure - an unmet need! J Hepatol. 2022;76(1):241-242. doi:10.1016/j.jhep.2021.06.046
Moolenaar LR, De Waard NE, Heger M, et al. Liver injury and acute liver failure after bariatric surgery: an overview of potential injury mechanisms. J Clin Gastroenterol. 2022;56(4):311-323. doi:10.1097/MCG.0000000000001662
King WC, Chen JY, Courcoulas AP, et al. Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study. Surg Obes Relat Dis. 2017;13(8):1392-1402. doi:10.1016/J.SOARD.2017.03.021
King WC, Chen JY, Mitchell JE, et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA. 2012;307(23):2516-2525. doi:10.1001/jama.2012.6147
Suzuki J, Haimovici F, Chang G. Alcohol use disorders after bariatric surgery. Obes Surg. 2012;22(2):201-207. doi:10.1007/s11695-010-0346-1
Kanji S, Wong E, Aikioyamen L, Melamed O, Taylor VH. Exploring pre-surgery and post-surgery substance use disorder and alcohol use disorder in bariatric surgery: a qualitative scoping review. Int J Obes (Lond). 2019;43(9):1659-1674. doi:10.1038/S41366-019-0397-X
Conason A, Teixeira J, Hsu CH, Puma L, Knafo D, Geliebter A. Substance use following bariatric weight loss surgery. JAMA Surg. 2013;148(2):145-150. doi:10.1001/2013.JAMASURG.265
Miller-Matero LR, Hamann A, LaLonde L, et al. Predictors of alcohol use after bariatric surgery. J Clin Psychol Med Settings. 2021;28(3):596-602. doi:10.1007/S10880-020-09751-3
Maluenda F, Csendes A, De Aretxabala X, et al. Alcohol absorption modification after a laparoscopic sleeve gastrectomy due to obesity. Obes Surg. 2010;20(6):744-748. doi:10.1007/S11695-010-0136-9
Acevedo MB, Eagon JC, Bartholow BD, Klein S, Bucholz KK, Pepino MY. Sleeve gastrectomy surgery: when 2 alcoholic drinks are converted to 4. Surg Obes Relat Dis. 2018;14(3):277-283. doi:10.1016/J.SOARD.2017.11.010
Svensson PA, Anveden Å, Romeo S, et al. Alcohol consumption and alcohol problems after bariatric surgery in the Swedish obese subjects study. Obesity. 2013;21(12):2444-2451. doi:10.1002/oby.20397
Östlund MP, Backman O, Marsk R, et al. Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery. JAMA Surg. 2013;148(4):374-377. doi:10.1001/JAMASURG.2013.700
Lefere S, Onghena L, Vanlander A, Nieuwenhove Y, Devisscher L, Geerts A. Bariatric surgery and the liver-mechanisms, benefits, and risks. Obes Rev. 2021;22:e13294. doi:10.1111/obr.13294
Lefere S, Stroobant L, Verhelst X, et al. Bariatric surgery patients are at risk for alcoholic liver disease with need for liver transplantation. Obes Surg. 2020;30(11):4659-4664. doi:10.1007/S11695-020-04806-8
Spadola CE, Wagner EF, Dillon FR, Trepka MJ, De La Cruz-Munoz N, Messiah SE. Alcohol and drug use among postoperative bariatric patients: a systematic review of the emerging research and its implications. Alcohol Clin Exp Res. 2015;39(9):1582-1601. doi:10.1111/ACER.12805
Xu R, Zhu C, Pierre JF, Yin DP. Gastric bypass improves obesity and glucose tolerance independent of gastric pouch size. Obes Surg. 2020;30(5):1635-1641. doi:10.1007/s11695-020-04403-9
Praveen Raj P, Gomes RM, Kumar S, et al. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial. Surg Obes Relat Dis. 2015;11(6):1315-1322. doi:10.1016/J.SOARD.2015.02.006
Ayer A, Borel F, Moreau F, et al. Techniques of sleeve gastrectomy and modified Roux-en-y gastric bypass in mice. J Vis Exp. 2017;2017:54905. doi:10.3791/54905
Cerón-Solano G, Zepeda RC, Romero Lozano JG, Roldán-Roldán G, Morin JP. Bariatric surgery and alcohol and substance abuse disorder: a systematic review. Cir Esp. 2021;99(9):635-647. doi:10.1016/j.ciresp.2021.03.006
Pepino MY, Okunade AL, Eagon JC, Bartholow BD, Bucholz K, Klein S. Effect of Roux-en-Y gastric bypass surgery: converting 2 alcoholic drinks to 4. JAMA Surg. 2015;150(11):1096-1098. doi:10.1001/JAMASURG.2015.1884
Backman O, Stockeld D, Rasmussen F, Näslund E, Marsk R. Alcohol and substance abuse, depression and suicide attempts after Roux-en-Y gastric bypass surgery. Br J Surg. 2016;103(10):1336-1342. doi:10.1002/BJS.10258
Steffen KJ, Engel SG, Wonderlich JA, Pollert GA, Sondag C. Alcohol and other addictive disorders following bariatric surgery: prevalence, risk factors and possible etiologies. Eur Eat Disord Rev. 2015;23(6):442-450. doi:10.1002/ERV.2399
Acevedo MB, Teran-Garcia M, Bucholz KK, et al. Alcohol sensitivity in women after undergoing bariatric surgery: a cross-sectional study. Surg Obes Relat Dis. 2020;16(4):536-544. doi:10.1016/j.soard.2020.01.014
Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753-761. doi:10.1056/NEJMOA066603
Auge M, Menahem B, Savey V, Lee Bion A, Alves A. Long-term complications after gastric bypass and sleeve gastrectomy: what information to give to patients and practitioners, and why? J Visc Surg. 2022;159(4):298-308. doi:10.1016/j.jviscsurg.2022.02.004

Auteurs

Louis Onghena (L)

Department for Human Structure and Repair, Department of Gastrointestinal Surgery, Ghent University, Ghent, Belgium.
Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Yves Van Nieuwenhove (Y)

Department for Human Structure and Repair, Department of Gastrointestinal Surgery, Ghent University, Ghent, Belgium.

Laurissa Demeulenaere (L)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Lindsey Devisscher (L)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Basic and Applied Medical Sciences, Gut-Liver Immunopharmacology Unit, Ghent University, Ghent, Belgium.

Xavier Verhelst (X)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Helena Degroote (H)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Sarah Raevens (S)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Hans Van Vlierberghe (H)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Sander Lefere (S)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Anja Geerts (A)

Liver Research Center Ghent, Ghent University, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Hepatology Research Unit, Ghent University, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH